A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer

Overview of attention for article published in Breast Cancer Research, August 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (73rd percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

news: 1 news outlet

Citations

dimensions_citation: 47 Dimensions

Readers on

mendeley: 71 Mendeley

Summary News Dimensions citations

So far, Altmetric has seen 1 news story.

Adjuvant Bevacizumab in High-Risk HER2-Negative Breast Cancer

The ASCO Post, 14 Sep 2018

By Matthew Stenger Posted: 8/6/2018 10:55:28 AM Last Updated: 9/14/2018 3:24:37 PM Advertisement The addition of bevacizumab…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.